Related Experiment Video
Updated: Feb 4, 2026

Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
Published on: June 7, 2012
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.
Jonathan Douxfils1,2,3, Marie Didembourg1,2, Lorraine Maitrot-Mantelet4
1Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, 5000 Namur, Belgium.
Relugolix combined therapy for uterine conditions shows a low venous thromboembolism (VTE) risk, comparable to traditional oral contraceptives. Careful patient selection and ongoing surveillance are recommended for optimal safety.
Area of Science:
- Pharmacology
- Gynecology
- Thrombosis Research
Background:
- Relugolix, an oral GnRH antagonist, treats uterine myomas and endometriosis.
- Concerns exist regarding venous thromboembolism (VTE) risk with relugolix combined with estradiol (E2) and norethisterone acetate (NETA).
Purpose of the Study:
- Evaluate the thrombotic risk of relugolix combined therapy (relugolix-CT).
- Assess risk based on pharmacological data, clinical trials, and regulatory reviews.
Main Methods:
- Reviewed pivotal trials (LIBERTY, SPIRIT) and regulatory reports (EMA, FDA).
- Analyzed real-world safety data, focusing on hemostatic effects and VTE risk.
Main Results:
- Relugolix monotherapy causes minor decreases in coagulation factors.
- E2 and NETA mitigate hypoestrogenic effects; clinical data show no significant VTE increase.
- E2-based regimens have lower thrombotic risk than ethinylestradiol-based therapies.
Conclusions:
- Relugolix-CT VTE risk appears lower than traditional combined oral contraceptives.
- Essential to select patients carefully, especially those with thrombotic risk factors.
- Continued real-world surveillance is crucial for refining the safety profile.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Relative Risk
Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
Venous Thrombosis I: Introduction
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

